Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy

NCT06767956 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped IND Sponsor-Investigator left institution

Conditions

Non Hodgkin Lymphoma

Interventions

DRUG: GOLCADOMIDE
DRUG: Nivolumab

Sponsor

University of Pittsburgh

Collaborators

[object Object]